ABBV vs ROIV
ABBV: A global biopharmaceutical leader focused on developing innovative, specialized therapies for immunology, oncology, neuroscience, and aesthetic medicine. ROIV: Roivant Sciences is a biopharma company that accelerates drug development through a decentralized model of nimble, independent 'Vant' subsidiaries and proprietary computational tools.
Side-by-side fundamentals
| Metric | ABBV | ROIV | Edge |
|---|---|---|---|
| Price as of 2026-08-07 close | $246.04 | $36.34 | |
| Market cap as of 2026-08-09 | $434.7B | $26.2B | |
| P/E as of 2026-08-09 | 119.61 | n/a | |
| PEG as of 2026-08-09 | 6.59 | n/a | |
| Net margin as of 2026-08-09 | +5.8% | -3629.2% | ABBV higher |
| Gross margin as of 2026-08-09 | +72.0% | +84.4% | ROIV higher |
| Operating margin as of 2026-08-09 | +24.4% | -6102.2% | ABBV higher |
| ROE as of 2026-08-09 | +95.6% | -6.9% | ABBV higher |
| ROA as of 2026-08-09 | +2.7% | -5.7% | ABBV higher |
| Debt / equity as of 2026-08-09 | 49.22 | 0.00 | ROIV lower |
| Revenue growth (YoY) as of 2026-08-09 | +9.5% | -89.2% | ABBV higher |
| Revenue CAGR (3y) SEC XBRL | +1.8% | -36.0% | ABBV higher |
| Dividend yield as of 2026-08-09 | +2.8% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-09 | 0.21 | 1.11 | |
| 1-year return as of 2026-08-07 close | +23.7% | +214.6% | ROIV higher |
Fundamentals: market data, as of 2026-08-09. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.